A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

NCT06245603 · tracked via the Priya Life Science Italy tracker

Sponsor

Istituto Oncologico Veneto IRCCS

Phase

Not applicable

Started

2024-12-20

Last updated

2026-08-04

Condition(s) studied

Non-muscle Invasive Bladder Cancer

Investigational drug(s) / intervention(s)

Hydeal Cyst®

Hydeal Cyst®: BCG or MMC will be started within 1-2 weeks from randomization (within 12-14 weeks after TURB). BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes. IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment. 48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation. BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation.

Study summary

Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject. Patients will be enrolled in the study only if they meet all the inclusion criteria and none of the exclusion criteria.

Prior to perform any study specific procedure (including screening procedures to determine eligibility), a signed informed consent form will be obtained for each subject. The informed consent form will describe the purpose of the study, the procedures to be followed, and the risk and benefits of participation. The investigator will conduct the informed consent discussion and will check that the subject comprehends the information provided and will answers any questions about the study. Consent will be voluntary and free from coercion. The investigator that will conduct the consent discussion will also sign the informed consent form. A copy of the informed consent form will be given to the subject and the fact that the subject has been consented to the study will be documented in the subject's record. When all the inclusion and exclusion criteria have been addressed and the eligibility of the subject confirmed, the subject may be enrolled in the study.

The following activities and/or assessments will be performed during screening, prior the treatment period start: demographic, medications related to the disease or symptoms and cancer history data collection; Urine-colture; randomization; Questionnaires QoL e IPSS.

BCG or MMC will be started within 1-2 weeks from randomization (within 12-14 weeks after TURB).

BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.

IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.

48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.

BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation.

After 2 weeks from BCG or MMC instillation end, IPSS e QoL questionaires will be administered and a control urino-colture will be executed.

After 6 and 18 weeks from instillation therapy end, a control visit will be made.

A physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.

Control cystoscopy and urino-colture will be executed (as for clinical practice) and IPSS and quality of life evaluated.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Male or female ≥ 18 years of age * ECOG PS 0-2 * Histologically confirmed diagnosis of non-muscle invasive bladder cancer, naïve and recurrent. * Patients candidate to BCG or MMC intravesical induction therapy. * Transurethral resection (TURB/re-TURB when indicated) performed in the last 12 weeks. * IPSS score ≤19 * Negative urine culture within 2 weeks before T0 * For women who are not postmenopausal (i.e., \< 1 year after last menstruation) or surgical-ly sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive de-vice, or barrier method of contraception in conjunction with spermicidal jelly) during the study period * Signed the study informed consent prior to any study specific procedures. * Will and ability to comply with the protocol Exclusion Criteria: * Upper urinary tract urothelial carcinoma (UTUC); bladder diverticula; urethral stenosis; difficult catheterization; reduced bladder compliance; increased bladder compliance; post-voiding residue \> 150 ml; * Surgery or invasive procedures planned during the study and interfering with evaluation about efficacy and safety of it. * Female patients with child-bearing potential must not be pregnant or lactating, or not willing to use adequate contraception for the duration of study * Pelvic radiotherapy within 24 weeks prior to the beginning of the study treatment. * Urinary tract infection requiring antibiotics * Have a known hypersensitivity to any substance present in the investigational device. * Neurogenic bladder * Any condition for that, in the opinion of the Investigator, participation would not be in the best interest of the subject.

Primary outcome measure(s)

Lower urinary tract symptoms — From the date of randomization up to 22 weeks
Lower urinary tract symptoms will be evaluated by the IPSS questionnaire (score 0-35) at baseline and follow-up visits. Difference from baseline will be calculated at two weeks after the end of induction cycle of intravesical instillation.

Trial sites (9)

Facility	City	Region	Status
Humanitas Gavezzeni-Bergamo	Bergamo	Italy	Recruiting
Ospedale Sant'Orsola - Malpighi	Bologna	Italy	Not Yet Recruiting
Policlinico Ospedali Riuniti - Foggia	Foggia	Italy	Recruiting
Istituto Oncologico Veneto IRCCS	Padova	Italy	Recruiting
Azienda Ospedale Università Padova	Padova	Italy	Recruiting
Ospedali Riuniti Padova Sud	Padova	Italy	Recruiting
Policlinico Paolo Giaccone	Palermo	Italy	Recruiting
Ospedale Santa Maria della Misericordia - ASU FC	Udine	Italy	Recruiting
Azienda Ospedaliera Universitaria Integrata - Verona	Verona	Italy	Recruiting

More Istituto Oncologico Veneto IRCCS trials in Italy

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer Active, not recruiting

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype Recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Active, not recruiting

Regorafenib for Recurrent Meningioma (MIRAGE Trial) Recruiting

VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures Recruiting

Other trials for the same condition

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Recruiting

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06245603 on ClinicalTrials.gov ↗ ← All trials in Italy